Want to see FDMT full AI Analyst Report?
Top Page
4D Molecular Therapeutics
(NASDAQ:FDMT)
Select Model
Select Model
Rating:56Neutral
Price Target:
$17.50
▲(73.78% Upside)
Action:Reiterated
Date:08/20/26
The score is held back primarily by weak financial performance: substantial net losses and significant operating/free-cash-flow burn persist despite improved revenue. Offsetting factors include strong technical momentum (though currently overbought) and positive corporate updates from encouraging clinical data and added financing capacity. Valuation remains constrained by the lack of profitability and a negative P/E.
Positive Factors
Sharp revenue growth
The substantial revenue step-up indicates stronger collaboration, licensing, or milestone activity. Although revenue may remain variable, a larger commercial and partnership base can improve funding capacity and support continued clinical development.
Negative Factors
Large and persistent net losses
FDMT remains far from breakeven despite higher revenue, leaving its outlook dependent on successful clinical execution and future financing or partnership proceeds. Continued losses can erode shareholder capital and limit strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Sharp revenue growth
The substantial revenue step-up indicates stronger collaboration, licensing, or milestone activity. Although revenue may remain variable, a larger commercial and partnership base can improve funding capacity and support continued clinical development.
Read all positive factors
4D Molecular Therapeutics (FDMT) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$874.52M
Dividend YieldN/A
Average Volume (3M)968.42K
Price to Earnings (P/E)―
Beta (1Y)0.62
Revenue Growth278712.12%
EPS Growth26.59%
CountryUS
Employees196
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.72
Shares Outstanding55,244,210
10 Day Avg. Volume698,244
30 Day Avg. Volume968,420
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$32.80Price Target Upside225.72% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.11
Revenue Forecast (FY)$13.18M
4D Molecular Therapeutics Business Overview & Revenue Model
Company Description
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a ...
How the Company Makes Money
FDMT primarily generates revenue through collaboration and licensing arrangements related to its proprietary AAV capsid/vector platform and associated intellectual property, rather than from product sales (as a clinical-stage company, it has histo...
4D Molecular Therapeutics Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
70
Positive
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 92.01M | 85.21M | 37.00K | 20.72M | 3.13M | 18.04M |
| Gross Profit | 38.65M | 77.58M | -141.26M | -76.37M | -77.12M | -43.32M |
| EBITDA | -184.87M | -132.48M | -154.16M | -96.63M | -105.09M | -69.79M |
| Net Income | -179.18M | -140.11M | -160.87M | -100.84M | -107.49M | -71.32M |
Balance Sheet | ||||||
| Total Assets | 492.62M | 566.71M | 560.38M | 339.89M | 261.85M | 353.49M |
| Cash, Cash Equivalents and Short-Term Investments | 361.33M | 402.65M | 424.88M | 288.23M | 213.55M | 247.78M |
| Total Debt | 39.22M | 21.41M | 24.61M | 14.67M | 16.12M | 16.45M |
| Total Liabilities | 84.96M | 61.05M | 49.78M | 32.06M | 30.51M | 34.38M |
| Stockholders Equity | 407.66M | 505.66M | 510.61M | 307.83M | 231.34M | 319.11M |
Cash Flow | ||||||
| Free Cash Flow | -156.67M | -109.08M | -138.37M | -78.56M | -98.22M | -78.24M |
| Operating Cash Flow | -156.07M | -109.08M | -134.59M | -75.79M | -86.69M | -69.13M |
| Investing Cash Flow | -16.64M | -92.97M | -302.44M | 115.72M | -17.05M | -172.68M |
| Financing Cash Flow | 165.92M | 112.96M | 337.25M | 156.83M | 3.08M | 118.09M |
4D Molecular Therapeutics Technical Analysis
Positive
10.07
Price Trends
11.51
Positive
10.51
Positive
9.89
Positive
Market Momentum
1.27
Negative
73.76
Negative
88.81
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FDMT, the sentiment is Positive. The current price of 10.07 is below the 20-day moving average (MA) of 11.91, below the 50-day MA of 11.51, and above the 200-day MA of 9.89, indicating a bullish trend. The MACD of 1.27 indicates Negative momentum. The RSI at 73.76 is Negative, neither overbought nor oversold. The STOCH value of 88.81 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FDMT.
4D Molecular Therapeutics Risk Analysis
4D Molecular Therapeutics disclosed 87 risk factors in its most recent earnings report. 4D Molecular Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
4D Molecular Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $700.00M | 62.51 | -0.02% | ― | 125.12% | 98.69% | |
56 Neutral | $874.52M | -5.82 | -41.33% | ― | 278712.12% | 26.59% | |
53 Neutral | $194.08M | -1.32 | -114.26% | ― | -62.08% | -2.62% | |
52 Neutral | $938.10M | -12.70 | -34.03% | ― | ― | -5.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $342.90M | -5.10 | -27.15% | ― | ― | 45.56% | |
39 Underperform | $808.90M | -4.38 | -73.18% | ― | ― | 9.05% |
* Healthcare Sector Average
FDMT
4D Molecular Therapeutics
15.83
9.09
134.87%
ASMB
Assembly Biosciences
34.38
7.76
29.15%
KRRO
Korro Bio
13.18
-6.89
-34.33%
DSGN
Design Therapeutics
14.99
9.79
188.27%
IMRX
Immuneering
5.30
-0.65
-10.92%
AURA
Aura Biosciences Inc
7.80
1.28
19.63%
4D Molecular Therapeutics Corporate Events
Business Operations and Strategy
4D Molecular Therapeutics Posts Strong 4D-150 Trial Results
Positive
Jul 20, 2026
On July 18, 2026, 4D Molecular Therapeutics reported positive two-year data from its PRISM Phase 2b clinical trial of 4D-150 in patients with broad wet age-related macular degeneration, based on a data cutoff of May 18, 2026. The study enrolled 45...
Business Operations and StrategyPrivate Placements and Financing
4D Molecular Therapeutics Secures $200 Million Loan Facility
Positive
Jun 29, 2026
On June 24, 2026, 4D Molecular Therapeutics entered into a senior secured Loan and Security Agreement with Hercules Capital that provides for up to $200 million in term loans maturing on June 1, 2031, with an initial $20 million drawn at closing a...
Executive/Board ChangesShareholder Meetings
4D Molecular Therapeutics Stockholders Back Directors and Governance
Positive
Jun 22, 2026
On June 17, 2026, 4D Molecular Therapeutics held its 2026 Annual Meeting of Stockholders virtually, with 44,038,022 of 52,274,735 eligible shares represented, and stockholders elected three Class III directors—Nancy Miller-Rich, John F. Mill...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.